Angirid MR 35 mg is a modified-release tablet containing Trimetazidine Dihydrochloride, a metabolic anti-ischemic agent manufactured by ACME Laboratories Ltd. in Bangladesh. It is primarily indicated as an add-on therapy for the symptomatic treatment of stable angina pectoris in patients who are inadequately controlled by or intolerant to first-line antianginal therapies